Applying a Pharmacometrics-Enabled Machine Learning Analysis to Predict 2-Month Culture Conversion Using Phase 2a Data in a Tuberculosis Clinical Trial
Abstract
Phase 2a trials in tuberculosis patients traditionally assess early bactericidal activity over two weeks, often using the time-to-positivity biomarker, followed by a phase 2b study typically lasting 8-week with time-to-event of culture conversion as the endpoint. This study investigated different machine learning models to predict the time-to-event of 2-month culture conversion in the REMoxTB trial with phase 2a time-to-positivity biomarker data and the impact of different phase 2a study lengths. Time-to-positivity at baseline and up to 14 days or 28 days after two moxifloxacin-containing regimens and one control regimen were analyzed using nonlinear mixed-effects modeling. The final models were used to predict individual baseline time-to-positivity and time-to-positivity differences between 0 and 14 days or 0 and 28 days. The individual predictions served as features in the following machine learning analysis. Statistical metrics and Kaplan-Meier plots informed model selection. Bi-exponential and exponential decay models described the 14-day and 28-day time-to-positivity data, respectively. In the machine learning analysis, baseline time-to-positivity and/or time-to-positivity differences were ranked as the most important features in all models. Statistical metrics and Kaplan-Meier plots indicated a good fit to culture conversion at 8 weeks using 4-week phase 2a information with a C-support vector classification model. Four-week time-to-positivity phase 2a data provided…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Synthesis, In Vitro and In Silico Molecular Docking Studies of Novel Phthalimide–Pyrimidine Hybrid Analogues to Thalidomide as Potent Antitubercular Agents
- Exploring the inhibitory performance of expired moxifloxacin and norfloxacin on copper corrosion in saline environment
- Molecular investigation of antimicrobial peptides against Helicobacter pylori proteins using a peptide-protein docking approach
- Screening of novel narrow-spectrum benzofuroxan derivatives for the treatment of multidrug-resistant tuberculosis through in silico, in vitro, and in vivo approaches
- Synthesis, Characterization, Anticancer, Antioxidant, and In Silico Evaluation of Semicarbazides and Thiosemicarbazides
- Fast and accurate prediction of drug induced proarrhythmic risk with sex specific cardiac emulators
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.